FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

When Dr Samson Magesa walked away from the busy wards of Mwananyamala Hospital a decade ago, he carried with him the frustrations of a medical professional who had witnessed too many patients ...

Profound Medical Corp. ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

For more information about Candel, visit: www.candeltx.com.

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing ...

Two ever-popular courses in Duke’s Master of Engineering for MedTech Design program led by industry-seasoned faculty ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...